Immupharma Share Discussion Threads

[tomboyb] 20/12/2021 10:33

On target -

That would make more sense -

The current share price at around 7p -

[glavey] 20/12/2021 10:33

'Cos someone's bound to come along and pay way over the top for some shares, of course. Happens every day. Doh!

[sicilian_kan] 20/12/2021 10:33

Agreed On Target. Your maths and selected use of figures GreatApeSpecies is appalling.

[on target] 20/12/2021 10:31

You need to add the cash that would be raised by the warrants if you're including them.

The Lanstead arrangement is a bit off-putting though, sounds a bit like a death-spiral type arrangement if you think about how it might work - clearly Lanstead are going to be selling each tranche of shares at whatever price and giving some of the proceeds to IMM and keeping the rest themselves, so will make money whatever the shareprice.

[husbod] 20/12/2021 10:29

Exactly the same here. It was a hard lesson learned- that successful Phase 1 and 2 trials don't mean phase 3 will succeed. Bought enough at the time to retire - teach me to be greedy but is our time now coming? Who knows but the signs look positive so I have averaged down and am hoping it's not a case of sending good money after bad.

[greatapespecies] 20/12/2021 10:25

Stats:

£3.55m raised.

Current shares in issue 250,221,297

Share subscribed:
Alora: 10,909,091
Lanstead: 20,000,000
Placing: 1,363,636

Warrants: 64,545,454

Lanstead sharing agreement shares: 1,400,000

Fee shares: 1,090,909.

Total shares and warrants: 99,309,090

Dilution to existing shareholders, using Sicilians fully diluted figure:
294,933,446 = 33.68%

£3.55m cash (may be more or less according to Lanstead production sharing agreement).
£3.55m / 99,309,090 shares implies a fully diluted fund raising price of 3.57p per share.

[sicilian_kan] 20/12/2021 10:13

Whatever one thinks of the long term prospects here - today's news is a massive buy signal. Avion, who have partnered with IMM and who already have the bulk of US Lupuzor anyway, and who also know more about the PK study, the current FDA position etc. than anyone else...They have chosen to buy £1.2m of IMM shares at 11p, announced today. You can buy the same shares at 7.5p. Yes there are risks, but I see this as a massive buy signal.

[mwainw1973] 20/12/2021 09:36

Strange action wait this one out with my core holding before seeing what happens

[tomboyb] 20/12/2021 09:21

Huge discount to prevailing share price -

I think its Lanstead -

Although Alora Pharmaceuticals LLC is also there at 11p -

[newbietrader2000] 20/12/2021 09:08

Cnt be placing holders to be selling at a lossSo what's the issue here

[spawny100] 20/12/2021 09:00

Weird. Raised funds at 11p - a huge premium yet can still buy for 7.4p. Had a dabble. Lost a lot on this a few years back and still don't trust dodgy Tim but seems like a no brainer if institutions see value at 11p.

[tomboyb] 20/12/2021 09:00

Too much of a discount -

[1bond] 20/12/2021 08:58

Where is the stinger today !!!!

[newbietrader2000] 20/12/2021 08:58

What's holding this back

[tomboyb] 20/12/2021 08:38

Breaking above 7p -

[rogerc1985] 20/12/2021 08:38

Longest auction i seen

[rogerc1985] 20/12/2021 08:37

10 min auction

[tomboyb] 20/12/2021 08:34

It won't stay at this price -

[rogerc1985] 20/12/2021 08:32

Why is it this low

[zen12] 20/12/2021 08:29

Should be 11p..big boys paying 11p no brainer!

[tomboyb] 20/12/2021 08:27

11p per share V 7p now -

w

[tomboyb] 20/12/2021 08:26

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce subscriptions and a placing to raise GBP3.55 million (the "Subscription(s)" and "Placing") through the issue of 32,272,727 new ordinary shares of 10 pence each in the Company ("Ordinary Shares") at a price of 11 pence per Ordinary Share ("Issue Price") utilising the maximum amount of existing authorities to allot shares. The Company has also entered into a sharing agreement ("Sharing Agreement") with Lanstead Capital Investors L.P. ("Lanstead|").

Highlights

-- Subscription for 10,909,091 new Ordinary Shares ("the Alora Subscription Shares") by Alora Pharmaceuticals LLC ("Alora"), the parent company of Avion Pharmaceuticals LLC ("Avion"), with whom the Company signed a licence and development agreement in November 2019 for the exclusive rights to Lupuzor(TM) in North America (United States), to raise GBP1.2 million (the "Alora Subscription").

-- Subscription for 20,000,000 new Ordinary Shares (the "Lanstead Subscription Shares") by Lanstead at an issue price of 11 pence per Subscription Share to raise GBP2.2 million (the "Lanstead Subscription").

-- Placing of 1,363,636 new Ordinary Shares ("Placing Shares") to raise GBP0.15 million (the "Placing").

-- The Issue Price represents a 80 per cent. premium to the closing mid-market price (of 6.1p) of the Ordinary Shares on 17 December 2021, the latest business date prior to the Subscriptions and Placing.

[tomboyb] 20/12/2021 08:25

What a great results! -

Just woken up late hols with kidz -